The maker of a promising ovarian cancer drug said, Friday, that he stopped enrolling women in a study because several patients developed gastrointestinal holes.
The study was postponed due to side effects
( z1 postpone :ARG1 ( z2 study ) :ARG1-of ( z3 cause :ARG0 ( z4 effect :mod ( z5 side ) ) ) )